| Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews R Pelletier, K Ng, W Alkabbani, Y Labib, N Mourad, JM Gamble Therapeutic Advances in Drug Safety 12, 2042098621989134, 2021 | 60 | 2021 |
| The association of sodium‐glucose cotransporter 2 inhibitors with cancer: an overview of quantitative systematic reviews R Pelletier, K Ng, W Alkabbani, Y Labib, N Mourad, JM Gamble Endocrinology, Diabetes & Metabolism 3 (3), e00145, 2020 | 25 | 2020 |
| Sodium/glucose cotransporter 2 inhibitors and the risk of diabetic Ketoacidosis: an example of complementary evidence for rare adverse events W Alkabbani, R Pelletier, JM Gamble American Journal of Epidemiology 190 (8), 1572-1581, 2021 | 12 | 2021 |
| Drug–drug interaction of the sodium glucose co-transporter 2 inhibitors with statins and myopathy: a disproportionality analysis using adverse events reporting data W Alkabbani, R Pelletier, MA Beazely, Y Labib, B Quan, JM Gamble Drug Safety 45 (3), 287-295, 2022 | 10 | 2022 |
| Assessing the risk of venous thromboembolism (VTE) in ambulatory patients with cancer: Rationale and implementation of a pharmacist-led VTE risk assessment program in an … R Pelletier Journal of Oncology Pharmacy Practice 27 (4), 911-918, 2021 | 3 | 2021 |
| Variation in bleeding risk estimates among online calculators: Cross-sectional study of apps used by and for patients with atrial fibrillation R Pelletier, J Nagge, JM Gamble Canadian Family Physician 68 (4), e127-e135, 2022 | 2 | 2022 |
JM GambleUniversity of WaterlooVerified email at uwaterloo.ca
